Acthrel market projected to grow as endocrine testing demand rises

The Business Research Company says the global Acthrel market is expanding on stronger demand for endocrine diagnostics, higher healthcare spending and rising endocrine disease prevalence. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2026-2035.

Why it matters: - Acthrel is used in diagnostic testing for adrenal and pituitary function, so market growth tracks broader demand for more precise endocrine care. - Rising use of diagnostic services, especially in hospital and specialty settings, is supporting demand for the drug and the testing protocols that rely on it. - The market’s expansion also reflects higher spending on healthcare and more cases of endocrine disorders that need targeted evaluation.

What happened: - The Business Research Company published its Acthrel Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the Acthrel market is experiencing notable developments driven by advances in diagnostic testing and rising healthcare needs. - The company says the market is set to expand steadily over the coming years as demand for endocrine evaluations grows. - The report places North America as the largest Acthrel market in 2025. - The report expects Asia-Pacific to be the fastest-growing region during the forecast period.

The details: - Acthrel, chemically known as corticorelin ovine triflutate, is a synthetic form of corticotropin-releasing hormone. - Acthrel is primarily used to evaluate hypothalamic-pituitary-adrenal, or HPA, axis function. - The drug helps detect adrenal insufficiency, distinguish causes of Cushing’s syndrome and assess pituitary gland function. - The report says historical growth came from the clinical need for accurate adrenal diagnostics, wider use in hospital diagnostics and regulatory approvals for diagnostic use. - Future growth is expected to be driven by rising endocrine disorder prevalence, demand for more precise diagnostic methods, expansion of specialty diagnostic centers, increased clinical research and greater use in advanced hospital laboratories. - Forecast trends include stronger use in endocrine diagnostic testing, more focus on HPA axis assessment, growth in specialized hormonal diagnostics, better differentiation of Cushing’s syndrome and broader adoption by advanced endocrinology centers. - The report links broader diagnostic demand to medical technology advances, stronger early-detection efforts, higher health awareness and an aging population. - The UK National Health Service reported diagnostic test volumes of 2,544,809 in 2024, up from 2,312,030 in 2023. - The report says rising healthcare spending is also supporting market growth. - UK Office for National Statistics data showed total healthcare spending rose 5.6% in nominal terms in 2023, a 0.9% increase from 2022. - The report says growing endocrine disease prevalence is lifting demand for Acthrel diagnostics. - UK National Health Service data showed 3,615,330 registered patients were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 in 2022. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 market reports also include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology analysis and future trend analysis.

Between the lines: - The report points to a market that is not driven by consumer demand, but by clinical workflows and diagnostic infrastructure. - Faster growth in Asia-Pacific suggests room for expanding lab capacity and endocrine care access in markets still building healthcare systems. - The emphasis on better differentiation of Cushing’s syndrome and more accurate HPA-axis assessment suggests Acthrel remains a specialized tool rather than a broad-use product.

What's next: - The report expects demand to rise as specialty diagnostic centers and advanced hospital laboratories expand. - Clinical research activity and improved endocrine diagnostics are likely to continue shaping adoption through 2035. - More detailed regional growth will depend on healthcare investment, disease detection rates and access to endocrine testing.

The bottom line: - Acthrel’s market outlook is tied to a larger shift toward more precise endocrine diagnosis, with North America leading today and Asia-Pacific set to outpace other regions in growth.